Related references
Note: Only part of the references are listed.Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial
Mikhail N. Kosiborod et al.
CIRCULATION (2020)
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Paul W. Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction A Prespecified Analysis of DAPA-HF
Kieran F. Docherty et al.
CIRCULATION (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction
Massar Omar et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial
Piotr Ponikowski et al.
LANCET (2020)
Recommended Heart Failure Medications and Adverse Drug Reactions in Women Call for Sex-Specific Data Reporting
Sophie H. Bots et al.
CIRCULATION (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women
Pooja Dewan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
The effect of dapagliflozin treatment on epicardial adipose tissue volume
Takao Sato et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes
W. Timothy Garvey et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2018)
Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials A Systematic Review
Ayman Samman Tahhan et al.
JAMA CARDIOLOGY (2018)
Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
Tsung-Ming Lee et al.
FREE RADICAL BIOLOGY AND MEDICINE (2017)
Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes
James L. Januzzi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Proposal of a Novel Mechanism of Action
Milton Packer et al.
JAMA CARDIOLOGY (2017)
Effect of Empagliflozin on the Metabolic Signature of Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease
Ben A. Kappel et al.
CIRCULATION (2017)
Gender differences in the effects of cardiovascular drugs
J. Tamargo et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2017)
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials
Sven Kohler et al.
ADVANCES IN THERAPY (2017)
Empagliflozin's Fuel Hypothesis: Not so Soon
Gary D. Lopaschuk et al.
CELL METABOLISM (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Cardiac Resynchronization Therapy in Women Versus Men Observational Comparative Effectiveness Study From the National Cardiovascular Data Registry
Robbert Zusterzeel et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2015)
Cardiac Resynchronization Therapy in Women Versus Men Observational Comparative Effectiveness Study From the National Cardiovascular Data Registry
Robbert Zusterzeel et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2015)
More Favorable Response to Cardiac Resynchronization Therapy in Women Than in Men
Yun-Jiu Cheng et al.
CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Safety and Tolerability of Canagliflozin in Patients With Type 2 Diabetes Mellitus: Pooled Analysis of Phase 3 Study Results
Keith Usiskin et al.
POSTGRADUATE MEDICINE (2014)
Left Bundle Branch Block Predicts Better Survival in Women Than Men Receiving Cardiac Resynchronization Therapy Long-Term Follow-Up of ∼145,000 Patients
Zak Loring et al.
JACC-HEART FAILURE (2013)
Sex-Related Differences in Myocardial Remodeling
Maddalena Piro et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
Karl Swedberg et al.
LANCET (2010)
The current state of knowledge on age, sex, and their interactions on clinical pharmacology
J. B. Schwartz
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Relationship of serum digoxin concentration to mortality and morbidity heart failure in women in the digitalis investigation group trial - A retrospective analysis
KF Adams et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases
N Jochmann et al.
EUROPEAN HEART JOURNAL (2005)
Female sex is associated with a better long-term survival in patients hospitalized with congestive heart failure
F Gustafsson et al.
EUROPEAN HEART JOURNAL (2004)
Gender differences in advanced heart failure: Insights from the BEST study
JK Ghali et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Sex-based differences in the effect of digoxin for the treatment of heart failure
SS Rathore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Gender differences in cardiac remodeling secondary to chronic volume overload
JD Gardner et al.
JOURNAL OF CARDIAC FAILURE (2002)
Share Paper
